Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Price:
59.11 CNY
-0.94%
Market Closed
Updated:
May 5, 2024
Hangzhou Tigermed Consulting Co Ltd
Operating Income
|
Hangzhou Tigermed Consulting Co Ltd
Operating Income Peer Comparison
Comparables:
603259
300759
2269
1548
M
688114
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Operating Income
¥1.7B
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
34%
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Operating Income
¥11.5B
|
CAGR 3-Years
52%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Operating Income
¥1.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Operating Income
¥4.4B
|
CAGR 3-Years
39%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Genscript Biotech Corp
HKEX:1548
|
Operating Income
-$314.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Operating Income
¥190.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Hangzhou Tigermed Consulting Co Ltd's Operating Income?
Operating Income
1.7B
CNY
1.7B
CNY
Based on the financial report for Dec 31, 2023, Hangzhou Tigermed Consulting Co Ltd's Operating Income amounts to 1.7B CNY.
What is Hangzhou Tigermed Consulting Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
34%
34%
Over the last year, the Operating Income growth was -4%. The average annual Operating Income growth rates for Hangzhou Tigermed Consulting Co Ltd have been 21% over the past three years , 22% over the past five years , and 34% over the past ten years .
You don't have any saved screeners yet
